Novo Nordisk fell more than 19 percent in premarket trading after the company reported weaker-than-expected data for its weight-loss drug Cagrisema, while Eli Lilly (LLY.N) rose nearly 6 percent in premarket trading.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up
to date with North American business news.
Weekly Highlights
A-share SMIC rose more than 5%
2024-12-27